Contributions from a diverse set of scientific disciplines will be needed to help individuals make fully informed decisions regarding contraceptive choices least likely to promote HIV susceptibility. This commentary recaps contrasting interpretations of results from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial, a study that compared HIV risk in women using the progestin-only injectable contraceptive depot medroxyprogesterone acetate (DMPA) vs. two other contraceptive choices. It also summarizes results from basic and translational research that establish biological plausibility for earlier clinical studies that identified enhanced HIV susceptibility in women using DMPA.

中文翻译：

---

HIV、孕激素、生殖器上皮屏障功能和客观性负担†。


需要来自不同科学学科的贡献，以帮助个人就最不可能增加艾滋病毒易感性的避孕选择做出充分知情的决定。本评论回顾了对避孕选择和艾滋病毒结果证据 (ECHO) 试验结果的对比解释，该研究比较了使用仅孕激素注射避孕药长效醋酸甲羟孕酮 (DMPA) 与其他两种避孕选择的女性的艾滋病毒风险。它还总结了基础研究和转化研究的结果，这些研究为早期临床研究确定了生物学合理性，这些研究发现使用 DMPA 会增强女性的 HIV 易感性。